TY  - JOUR
AU  - Dickinson, Michael
AU  - Cherif, Honar
AU  - Fenaux, Pierre
AU  - Mittelman, Moshe
AU  - Verma, Amit
AU  - Portella, Maria Socorro O
AU  - Burgess, Paul
AU  - Ramos, Pedro Marques
AU  - Choi, Jeea
AU  - Platzbecker, Uwe
AU  - SUPPORT study investigators
PY  - 2018
DO  - 10.1182/blood-2018-06-855221
UR  - https://hdl.handle.net/10668/27323
T2  - Blood
AB  - Azacitidine treatment of myelodysplastic syndromes (MDSs) generally exacerbates thrombocytopenia during the first treatment cycles. A Study of Eltrombopag in Myelodysplastic Syndromes Receiving Azacitidine (SUPPORT), a phase 3, randomized,...
LA  - en
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Azacitidine
KW  - Benzoates
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Hydrazines
KW  - Male
KW  - Middle Aged
KW  - Myelodysplastic Syndromes
KW  - Platelet Transfusion
KW  - Pyrazoles
KW  - Risk Factors
KW  - Thrombocytopenia
TI  - Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.
TY  - research article
VL  - 132
ER  -